Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CLGN logo CLGN
Upturn stock ratingUpturn stock rating
CLGN logo

Collplant Biotechnologies Ltd (CLGN)

Upturn stock ratingUpturn stock rating
$1.36
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CLGN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $12

1 Year Target Price $12

Analysts Price Target For last 52 week
$12Target price
Low$1.32
Current$1.36
high$5.48

Analysis of Past Performance

Type Stock
Historic Profit -55.46%
Avg. Invested days 15
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 17.55M USD
Price to earnings Ratio -
1Y Target Price 12
Price to earnings Ratio -
1Y Target Price 12
Volume (30-day avg) 1
Beta 0.86
52 Weeks Range 1.32 - 5.48
Updated Date 06/29/2025
52 Weeks Range 1.32 - 5.48
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.21

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -80.2%

Management Effectiveness

Return on Assets (TTM) -38.34%
Return on Equity (TTM) -75.27%

Valuation

Trailing PE -
Forward PE 15.55
Enterprise Value 9656099
Price to Sales(TTM) 7.1
Enterprise Value 9656099
Price to Sales(TTM) 7.1
Enterprise Value to Revenue 3.91
Enterprise Value to EBITDA -5.97
Shares Outstanding 12716000
Shares Floating 7651729
Shares Outstanding 12716000
Shares Floating 7651729
Percent Insiders 10.16
Percent Institutions 12.23

Analyst Ratings

Rating 1
Target Price 12
Buy -
Strong Buy 1
Buy -
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Collplant Biotechnologies Ltd

stock logo

Company Overview

overview logo History and Background

Collplant Biotechnologies Ltd. was founded in 2004, focusing on recombinant human collagen-based regenerative and aesthetic medicine products. It leverages its BioCollagen technology for tissue repair products.

business area logo Core Business Areas

  • Regenerative Medicine: Development and commercialization of products for tissue repair and regeneration, including orthopedic and wound healing applications.
  • Aesthetic Medicine: Development of dermal fillers and other aesthetic products based on recombinant human collagen.

leadership logo Leadership and Structure

Yehiel Tal is the CEO. The company has a board of directors and operates with distinct research, development, and commercial departments.

Top Products and Market Share

overview logo Key Offerings

  • VerteOss: A bone void filler used in orthopedic surgeries. Market share is still developing; specific figures are not readily available. Competitors include Medtronic (MDT), Stryker (SYK), and Johnson & Johnson (JNJ) with their bone graft substitutes.
  • rhCollagen: Recombinant human collagen used as a raw material for various applications, including medical and cosmetic products. Market share not readily available; faces competition from bovine and porcine collagen products and synthetic alternatives. Examples of competition are Integra LifeSciences (IART) and Zimmer Biomet (ZBH)

Market Dynamics

industry overview logo Industry Overview

The regenerative medicine industry is growing, driven by aging populations and increasing demand for minimally invasive procedures. The market is competitive, with established players and emerging biotechnology companies.

Positioning

Collplant is positioned as an innovator in recombinant human collagen technology, differentiating itself through its plant-based production platform. It aims to capture market share through partnerships and product development.

Total Addressable Market (TAM)

The total market value for regenerative medicine is estimated to be in the tens of billions of dollars and continue to grow. Collplant aims to capture a portion of this market through its proprietary technology and product pipeline.

Upturn SWOT Analysis

Strengths

  • Proprietary rhCollagen technology
  • Plant-based production platform
  • Strategic partnerships
  • Potential for innovative products

Weaknesses

  • Limited commercial product portfolio
  • Reliance on partnerships
  • High research and development costs
  • Negative earnings and negative cash flow

Opportunities

  • Expanding regenerative medicine market
  • Potential for new product applications
  • Geographic expansion
  • Partnerships with larger companies

Threats

  • Competition from established players
  • Regulatory hurdles
  • Technological advancements by competitors
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • SYK
  • JNJ
  • IART
  • ZBH

Competitive Landscape

Collplant is a smaller player compared to its competitors, focusing on innovative technology. It competes on product differentiation and strategic partnerships.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been dependent on partnerships and product approvals. More specific data needs to be based on actual revenues.

Future Projections: Analyst projections will vary. The company expects to grow due to VerteOss sales and new product development.

Recent Initiatives: Focus on expansion of VerteOss sales, exploring new rhCollagen applications.

Summary

Collplant Biotechnologies Ltd. is an innovative company with a unique technology platform. While the company has promising technology, it currently faces significant financial challenges and is heavily reliant on partnerships. Its strengths lie in its proprietary rhCollagen, but it must overcome commercialization hurdles and competition to achieve sustained growth. Investors should closely monitor their progress in sales of VerteOss and other pipeline projects.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Collplant Biotechnologies Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2018-01-30
CEO & Director Mr. Yehiel Tal
Sector Healthcare
Industry Biotechnology
Full time employees 57
Full time employees 57

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.